Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Coronary Cocr Stent Equipment Supplied In Europe
18 equipment items found
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
CoCr Stent Platform. Reliable durable polymer-Styrene Butylenes Styrene. Uniform sine wave design provides uniform support strength and ...
Manufactured by:Seleon GmbH based inHeilbronn, GERMANY
Several steps can be completed in one with the device. The protective cap is removed from the stent with the operation of the lever, and at the same time, the drug is applied and dried with sterile ...
Manufactured by:Translumina GmbH based inHechingen, GERMANY
The Translumina Yukon® CC represents a new generation of stent system technology based on a Cobalt-Chromium alloy. It is the first CoCr Stent with a unique micro-porous surface. The Yukon CC is in continuation of the Translumina Surface philosophy, improving healing and biocompatibility of the ...
Manufactured by:Sahajanand Medical Technologies Ltd. based inSurat, INDIA
Supraflex Cruz is an amalgamation of the best-in-class features like lowest strut thickness (60 μm), biodegradable polymer and offers an extensive size ...
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
Extraordinary Deliverability. Ultra Low Profile. Target Eluting Technology of ...
Manufactured by:MicroPort Scientific Corporation based inShanghai, CHINA
TARGET All Comers Trial: 1,656 Patients from 20 sites in Europe. 1:1 RCT Real World open-label, non-inferiority trial Primary endpoint: TLF @12 months. Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe. and effective across a broad spectrum of patient and lesion complexity. ...
Manufactured by:Tsunamed, Part of Q3 Medical Group based inWinsen, GERMANY
The MAGMA Rapamycin-Eluting Coronary Stent System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Rapamycin (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic ...
Manufactured by:Stron Medical, Part of Q3 Medical Group based inWinsen, GERMANY
The GALAXY Rapamycin-Eluting Coronary Stent System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Rapamycin (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic ...
Manufactured by:CARDIONOVUM GmbH based inBonn, GERMANY
The treatment of the heart requires superior medical device safety with predictable clinical efficacy. ...
Manufactured by:amg International GmbH based inWinsen, GERMANY
The ITRIXII Sirolimus-Eluting Coronary Stent Implantation System is the first carbonized stent (Inert Carbon Technology) with a completely biodegradable polymer coating which contains Sirolimus (Rapasorb™) as a highly effective drug for preventing thrombotic and re-stenotic ...
Manufactured by:CARDIONOVUM GmbH based inBonn, GERMANY
Unmatched XLIMUS clinical performance. The ultimate DES for complex artery lesions. XLIMUS is considered as the ultimate coronary DES stent system to treat complex coronary artery disease by reaching and crossing the most challenging ...
Manufactured by:Bentley InnoMed GmbH based inHechingen, GERMANY
This extraordinary product combines a highly flexible one-layer stent graft with a low-profile balloon catheter to offer an unrivalled small guiding catheter compatibility. The cobalt-chrome stent platform is covered with a micro-porous ePTFE membrane. The BeGraft Coronary Stent System is not for available in the ...
Manufactured by:P+F Products + Features GMBH based inVienna, AUSTRIA
The EFIL+ Sirolimus Eluting Stent System is a combination product comprised of two regulated components: a device (a coronary stent system) and a drug product (a formulation of Sirolimus contained in a polymer coating) pre mounted on balloon catheter between two platinum iridium radio opaque marker bands. EFIL+ uses a validated formulation of low dose Sirolimus (1.30µg/mm ) timed to elute ...
Manufactured by:Becton Dickinson and Company (BD) based inFranklin Lakes, NEW JERSEY (USA)
Tepha is developing fully absorbable stents and coatings made from TephaFLEX® material. This could allow for local drug elution while leaving no permanent residual polymer, which might address the issue of late stent thrombosis with current DESs. In addition, Tepha is developing fully absorbable polymer stents containing TephaFLEX® material, which would provide the necessary support ...
Manufactured by:Concept Medical Inc. based inTampa, FLORIDA (USA)
ABLUMINUS DES+ designed by propriety ENVISOLUTION technology in a way that address the unmet clinical needs specially in Diabetes Mellitus and Acute Myocardial infarction patients with Coronary Artery Disease. ABLUMINUS DES+ Receives on-label indication for Diabetes Mellitus and Acute Myocardial infarction. ...
Manufactured by:Translumina GmbH based inHechingen, GERMANY
The Translumina Yukon Choice PC drug-eluting stent, coated with Rapamycin (Sirolimus) and the biodegradable component polylactide (PLA), has an excellent history of pre-clinical and long-term clinical ...
Manufactured by:Translumina GmbH based inHechingen, GERMANY
The Translumina Yukon drug-eluting stent product family, coated with Rapamycin (Sirolimus) and the biodegradable component polylactide (PLA), has an excellent history of pre-clinical and long-term clinical ...
Manufactured by:CellProthera based inMulhouse, FRANCE
The unique therapeutic approach proposed by CellProthera is protected by various patents. It requires a simple blood sampling best performed within 2 weeks following a severe AMI. The sampling occurs after a treatment period using GCSF in order to mobilize the patient’s own stem cells into the blood flow. The patient’s blood sample is then forwarded to a local certified Cell Therapy ...